Avibactam Sodium

CHEMBL2107817 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

287.2 g/mol

LogP

—

Phase

4

The sodium salt of avibactam, formulated for intravenous use in combination with ceftazidime to treat serious infections caused by drug-resistant Gram-negative bacteria. By protecting the partner antibiotic from enzymatic destruction, it restores its bactericidal activity.

分子量

287.2300 g/mol

TPSA

141.00 Å²

治疗领域

Infectious Disease

作用机制

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)[O-].[Na+]

InChI

InChI=1S/C7H11N3O6S.Na/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15;/h4-5H,1-3H2,(H2,8,11)(H,13,14,15);/q;+1/p-1/t4-,5+;/m1./s1

Molecular Formula

C7H10N3NaO6S

HBD / HBA

1 / 6

可旋转键数

3

重原子数

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

The sodium salt of avibactam, formulated for intravenous use in combination with ceftazidime to treat serious infections caused by drug-resistant Gram-negative bacteria. By protecting the partner antibiotic from enzymatic destruction, it restores its bactericidal activity.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Avibactam Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107817. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 24944097. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

正在寻找患者友好型信息？

Avibactam Sodium 在 PillFYI 上

结构

快速数据

分子式: C7H10N3NaO6S

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.